Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
vrus5aTEW7CNgqSt
